# Autophagy Escape in ER-Positive Breast Cancer
This topic is **not only for people with a known TP53 tumor mutation**.
The broader issue is that **ER-positive, HER2-negative breast cancer** can adapt to treatment pressure through metabolic rewiring, dormancy programs, and **autophagy-based survival**.
Loss of **TP53** inside the tumor can intensify that pattern. It is not the only reason the pattern matters.
For related context, also see [Endocrine Therapy, Stable Disease, and Dormancy in ER-Positive Breast Cancer](/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/endocrine-therapy-stable-disease-and-dormancy-in-er-positive-breast-cancer.md), [AI Resistance and the 4-OHE1/E2 Pathway](/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/ai-resistance-and-the-4-ohe1-e2-pathway.md), and [CDK4/6 Options and Supplement Considerations](/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/cdk4-6-options-and-supplement-considerations.md).
If you want the fuller review-based walkthrough, also see [Autophagy and Senescence in Antiestrogen Resistance](/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/autophagy-and-senescence-in-antiestrogen-resistance.md).
### Jump menu
* [Big picture](#big-picture)
* [Where TP53 fits without making it the whole story](#where-tp53-fits-without-making-it-the-whole-story)
* [mTOR and glycolysis tilt](#mtor-and-glycolysis-tilt)
* [PI3K inhibition and autophagy escape](#pi3k-inhibition-and-autophagy-escape)
* [What comprehensive genomic profiling can and cannot tell you](#what-comprehensive-genomic-profiling-can-and-cannot-tell-you)
* [Where hydroxychloroquine fits in the treatment sequence](#where-hydroxychloroquine-fits-in-the-treatment-sequence)
* [Supplements that press on mTOR](#supplements-that-press-on-mtor)
* [Questions for your oncologist](#questions-for-your-oncologist)
* [Practical wording for member education](#practical-wording-for-member-education)
* [In a nutshell](#in-a-nutshell)
* [Notes on evidence depth](#notes-on-evidence-depth)
* [Key references](#key-references)
### Big picture
A simple way to frame this pathway is: **loss of a growth brake can push the tumour harder toward mTOR signalling and glycolysis, endocrine therapy and CDK4/6 treatment can favour dormant survival states, PI3K inhibition adds more stress, and autophagy can become a backup survival route**.
That helps explain why some integrative clinicians and researchers are strongly considering **autophagy inhibition** as a possible adjunct strategy in **ER-positive breast cancer**.
It also helps explain why supplements that modulate **mTOR** or **autophagy** deserve caution rather than casual stacking.
### Where TP53 fits without making it the whole story
Normal **p53** helps cells pause the cell cycle, repair DNA, trigger apoptosis, and coordinate stress responses when damage becomes too great.
When **TP53** is lost or functionally disabled, tumour cells can keep dividing despite genomic damage and become more adaptable under treatment pressure. In practical terms, a **TP53-null** or non-functional state usually signals a tumour that has lost an important checkpoint and may behave more aggressively.
Across all tumour types, the overall frequency of **TP53** mutations in established cancers is roughly **40–50%**, with higher rates in some cancers, reaching about **70–90%** in a few, and lower rates in others.
In breast cancer, **TP53-mutant tumours** are more likely to show a shift toward glycolysis and growth-promoting signalling such as the **PI3K/AKT/mTOR** axis.
That said, the treatment-relevance of autophagy is **not limited to patients who know their p53 status**. The reason this page sits in the ER-positive section is that the endocrine, CDK4/6, dormancy, and PI3K-pressure can drive up autophagy even when a TP53 result is unknown or not clearly actionable.
### mTOR and glycolysis tilt
Breast cancers with **TP53 mutation** show metabolic reprogramming, including increased expression of glycolysis-related genes and higher glycolytic activity compared with **TP53 wild-type** tumours.
**TP53** normally restrains glycolysis and negatively regulates **AKT/mTOR-related signalling**, so losing p53 can remove that restraint and favour anabolic growth.
This helps explain why **TP53-mutant tumours** are often described as being biased toward **mTOR activity**, **glucose use**, and broader growth signalling.
If a tumour with this biology is treated with **endocrine therapy**, **CDK4/6 inhibition**, and later a **PI3K inhibitor** such as **alpelisib**, the cancer cell may increasingly rely on **autophagy** as a survival program rather than dying outright.
### PI3K inhibition and autophagy escape
In **ER-positive breast cancer**, **PI3K-pathway inhibition** can reduce **AKT** signalling and relieve **mTORC1-driven** suppression of autophagy. That allows tumour cells to enter a stress-adaptation mode.
Preclinical work in ER-positive models showed that **PI3K inhibition induced autophagy**, while adding **chloroquine** blocked that autophagy and increased apoptosis.
That supports the idea that, in this setting, autophagy often acts less like a clean-up benefit and more like an **escape hatch** for cancer cells under treatment stress.
Autophagy is not only relevant after **PI3K inhibition**. In ER-positive breast cancer, autophagy has also been implicated in **endocrine resistance**, the survival of **dormant cells**, and treatment adaptation during the **CDK4/6 era**.
That is why some researchers are asking whether **hydroxychloroquine** may be worth considering earlier, rather than only after resistance becomes more entrenched.
### What comprehensive genomic profiling can and can*not* tell you
Nothing directly. But it can offer **strong clues**.
Commercial profiling platforms such as **FoundationOne** and **Omico-linked CGP workflows** are mainly built to match tumours to drugs and trials.
They do **not** directly measure autophagy.
They also do not usually label a tumour as **autophagy-dependent**.
What they can give is a **pattern**.
If a report shows changes such as **TP53**, **PIK3CA**, **PTEN**, **AKT1**, or **ESR1**, that can point to the kind of metabolic and treatment stress where autophagy becomes a survival tool.
For example, a tumour with **TP53 loss-of-function** plus **PI3K-pathway activation** may be more tilted toward **mTOR signalling**, **glycolysis**, and stress adaptation.
If **ESR1** mutations later appear, that adds another clue that surviving cells are learning to live through endocrine pressure rather than being eliminated by it.
In that setting, it is reasonable to **suspect** that autophagy is helping the cancer cope, especially during **endocrine therapy**, **CDK4/6 inhibition**, or **PI3K inhibition**.
The report itself still does not measure autophagy directly.
If an expensive profiling report feels incomplete on this question, that reaction makes sense.
These platforms were not built to tell the full story of **dormancy**, **metabolism**, or **autophagy**.
They can still help identify which tumours are more likely to lean on those survival pathways and which questions are worth taking back to the oncology team.
{% hint style="warning" %}
**So far, even with everything we know, the system still is not built to help much here.**
**Hydroxychloroquine** is a good example of that gap.
It clearly inhibits autophagy in preclinical models and already has long-standing FDA approval outside oncology.
Standard genomic reports still do not interpret results through an **autophagy-and-HCQ** lens.
Instead, they stay focused on mutations tied to targeted drugs and trial matching.
That leaves an old, cheap, off-patent drug like **HCQ** parked in the **off-label adjunct** bucket.
In practice, even when there is a strong biological case for autophagy inhibition in a **TP53-mutant**, **PIK3CA-mutant**, endocrine-resistant tumour, that story usually will not appear in the official report or guidelines any time soon.
Until there are large positive trials and a clearer commercial pathway, this strategy is more likely to come from informed patients and integrative clinicians than from standard profiling workflows.
{% endhint %}
### Where hydroxychloroquine fits in the treatment sequence
Preclinical work showed that **hydroxychloroquine** can potentiate anti-estrogen responsiveness in resistant **ER-positive** models. More recently, a **phase I trial** explored adding **hydroxychloroquine** to **palbociclib** and **letrozole** in **ER-positive/HER2-negative metastatic breast cancer**. That reflects growing interest in earlier autophagy targeting rather than waiting until **PI3K-directed treatment** is the only remaining biologic pressure point.
{% hint style="warning" %}
**Hydroxychloroquine is already FDA-approved for malaria and autoimmune disease, but its use in oncology remains repurposed, off-label, and protocol-sensitive.**
It also brings real monitoring needs, including eye safety, heart-rhythm review, liver testing, and drug-interaction checks.
{% endhint %}
### Supplements that press on mTOR
Among commonly discussed adjuncts, **curcumin** has some of the clearest preclinical evidence for suppressing **Akt/mTOR signalling**, including effects on **mTORC1** and **mTORC2** outputs.
However, natural compounds that inhibit **mTOR** can also induce **autophagy**, and in some settings that autophagy is protective for the tumour rather than harmful.
For this reason, **mTOR-modulating supplements** are best used with eyes wide open to the autophagy situation, with close attention to tolerance, liver tests, and whether the patient is already on a **PI3K inhibitor** such as **alpelisib.**
### Questions for your oncologist
1. In someone with **ER-positive metastatic breast cancer** receiving endocrine therapy with or without a **CDK4/6 inhibitor**, do you see a rationale for considering **autophagy inhibition earlier** to target dormancy and resistance, rather than waiting until progression on **PI3K-directed therapy**?
2. If **hydroxychloroquine** were considered in this setting, at what point in the treatment sequence would you regard it as most reasonable?
3. What monitoring would you want in place for **eyes, heart rhythm, liver function, and drug interactions** before and during treatment?
### Practical wording for member education
This is one practical way to explain the pathway.
**A lost or weakened growth brake can push the tumour harder toward mTOR signalling and glycolysis. Endocrine therapy and CDK4/6 treatment can help create dormant survival states. PI3K inhibition adds another layer of stress. Autophagy can then become a backup survival route.**
That framework helps explain why some patients ask about **hydroxychloroquine** and why supplements that influence **mTOR** or **autophagy** should be approached thoughtfully rather than stacked indiscriminately.
### In a nutshell
**TP53-null / non-functional p53**\
→ loss of a major growth and damage-response brake\
→ tumour leans harder on **PI3K/AKT/mTOR** and glycolysis for energy and growth (both with and without functional tp53)\
→ endocrine therapy (**AI / SERD**) plus **CDK4/6 inhibitors** squeeze this system\
→ many cancer cells die, but some adapt into stressed, often dormant survival states\
→ adding **PI3K inhibition** such as **alpelisib** or mTOR inhibitor increases metabolic and signalling stress further\
→ the surviving cancer cells switch on autophagy as a clean-up and energy-recycling program\
→ autophagy becomes a backup survival route that can help the tumour outlast treatment\
→ this is the biological window where autophagy inhibition, such as **HCQ** in trials, is being explored as a way to block that escape hatch
### Notes on evidence depth
**Hydroxychloroquine** has long-standing FDA-approved uses outside oncology, but cancer use remains **repurposed and investigational**.
A 2017 review noted that more than **30 clinical studies** were evaluating **chloroquine** and **hydroxychloroquine** across cancer settings at that time, and the oncology literature has continued to expand since then.
That makes **HCQ** one of the better-studied repurposed autophagy inhibitors in oncology, even though it is still **not standard of care** for **ER-positive metastatic breast cancer**.
The evidence is strongest for **mechanistic rationale**, **preclinical combination work**, and **early-phase clinical exploration**. It is weaker for definitive outcome proof in routine ER-positive practice.
Human breast-cancer studies using hydroxychloroquine
#### 1. Metastatic ER-positive disease on hormonal therapy
**ABC01** — `NCT02414776`
Registry: [ClinicalTrials.gov entry for ABC01 / NCT02414776](https://clinicaltrials.gov/study/NCT02414776)
This phase Ib/II study tested **hydroxychloroquine** added to ongoing hormonal therapy in **metastatic ER-positive breast cancer** after progression.
The goal was to assess safety, tolerability, and combination activity.
It was not a **hydroxychloroquine monotherapy** trial.
Public registry reporting points more toward disease-free or response-oriented combination outcomes.
It does not provide a clean **progression-free survival** comparison for **HCQ alone** versus no **HCQ**.
#### 2. Dormant or minimal-residual-disease settings
**CLEVER pilot** — `NCT03032406`
Registry: [ClinicalTrials.gov entry for CLEVER / NCT03032406](https://clinicaltrials.gov/study/NCT03032406)
This work studied breast-cancer survivors with bone-marrow **disseminated tumour cells** after primary treatment.
Some participants received **hydroxychloroquine** alone for several months.
Across the pilot data, detectable dormant-cell burden fell substantially versus observation.
These were small, dormancy-focused studies.
They were not classic metastatic **PFS** trials.
They also mix **HCQ**, **everolimus**, combination treatment, and observation rather than a clean **HCQ monotherapy versus control** design.
#### 3. Prevention and early-stage dormancy trials
**PALAVY**, **ABBY**, and related studies place **hydroxychloroquine** in prevention or early-stage residual-disease settings.
These trials aim to target dormant cells or micrometastatic disease.
**HCQ** is usually paired with other agents, including **immunotherapy** or **CDK4/6-directed** treatment.
These studies are relevant to dormancy biology.
They do not test **HCQ monotherapy** in metastatic breast cancer.
Direct registry naming is clearest for **ABC01** and **CLEVER**.
#### Takeaway
Human breast-cancer studies using **hydroxychloroquine** do exist.
The signal is mostly in **combination therapy** or **dormancy-directed** settings.
There is still no clean randomised metastatic **HCQ monotherapy versus control** trial that isolates **PFS** benefit from **HCQ** itself.
### Key references
* [TP53 mutation hits energy metabolism and increases glycolysis in breast cancer cells and induces a druggable oxidative phosphorylation phenotype (2016)](https://pubmed.ncbi.nlm.nih.gov/27582538/)
* [Targeting p53 pathways: mechanisms, structures and advances in drug discovery (2023)](https://www.nature.com/articles/s41392-023-01347-1)
* [Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5892720/)
* [Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumors (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9746060/)
* [Clinical and analytical validation of FoundationOne CDx, a comprehensive genomic profiling assay for solid tumors (2022)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0264138)
* [Autophagy and senescence facilitate the development of anti-estrogen resistance and aggressiveness in breast cancer cells (2024)](https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1298423/full)
* [Autophagy and Endocrine Resistance in Breast Cancer (2011)](https://pubmed.ncbi.nlm.nih.gov/21916582/)
* [Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4073207/)
* [Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2− metastatic breast cancer (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11770068/)
* [chloroquine and hydroxychloroquine as anti-cancer agents (2017)](https://pubmed.ncbi.nlm.nih.gov/29225688/)
* [Hydroxychloroquine: An Old Drug With New Relevance (2018)](https://pubmed.ncbi.nlm.nih.gov/29883308/)
* [Targeting Autophagy with Natural Compounds in Cancer: A Renewed Perspective from Molecular Mechanisms to Targeted Therapy (2021)](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.748149/full)
* [Curcumin induces autophagy, inhibits proliferation and invasion by downregulating AKT/mTOR signaling pathway in human melanoma cells (2016)](https://pubmed.ncbi.nlm.nih.gov/26573768/)
* [Autophagy Modulation in Therapeutic Strategy of Breast Cancer (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11375553/)
* [Autophagy facilitates the progression of ERalpha-positive breast cancer cells to antiestrogen resistant states (2009)](https://pubmed.ncbi.nlm.nih.gov/19221464/)
* [Resistance to hormone therapy in breast cancer cells promotes autophagy with concomitant apoptosis evasion (2023)](https://journals.physiology.org/doi/abs/10.1152/ajpcell.00199.2023)
* [Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence (2018)](https://www.nature.com/articles/s41467-018-04070-6)
* [Clinical utility of comprehensive genomic profiling in Japan (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8970371/)
---
# Agent Instructions: Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter:
```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/autophagy-escape-in-er-positive-breast-cancer.md?ask=
```
The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.